- Home
- » Tags
- » Camrelizumab
Top View
- The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
- Changes to International Nonproprietary Names for Antibody Therapeutics 2017 and Beyond: of Mice, Men and More
- Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
- Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4 Shuang Qin1, Linping Xu2, Ming Yi1, Shengnan Yu1, Kongming Wu1,2* and Suxia Luo2*
- Immunotherapy of Lymphomas
- Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
- Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Full Abbreviations, Accreditation, and Disclosure Information Available at Peerview.Com/EKR40
- Camrelizumab in Combination with Apatinib in Second-Line Or Above Therapy for Advanced Primary Liver Cancer
- QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
- Application for the Addition of Tislelizumab on the WHO Model List of Essential Medicines
- Medical Product Quality Report
- Medical Product Quality Report – COVID-19 Issues
- Biosimilar Monoclonalantibodies
- PD-1 Inhibitors on the Horizon for NSCLC: Current Knowledge, Future Possibilities
- Targeted Therapy for Hepatocellular Carcinoma
- Changes to International Nonproprietary Names for Antibody Therapeutics 2017 and Beyond: of Mice, Men and More
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- 184.Full.Pdf
- Antibodies to Watch in 2018